Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Prior therapy with cetuximab, panitumumab or other agent that targets EGFR
Prior exposure to any biologic
Known sensitivity to cetuximab or 5-FU (or marked intolerance to 5-FU)
Known DPD deficiency
Uncontrolled angina or a myocardial infarction within the previous 12 months
Concurrent severe uncontrolled medical illness
Known uncontrolled CNS metastases
Bowel disease associated with chronic diarrhea
Major surgery within 28 days
Clareo Health | Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
